Imaging of tumor angiogenesis: current approaches and future prospects
- PMID: 16842165
- DOI: 10.2174/138161206777698774
Imaging of tumor angiogenesis: current approaches and future prospects
Abstract
Tumor angiogenesis imaging should provide non-invasive assays of tumor vascular characteristics to supplement the now conventional diagnostic imaging goals of depicting tumor location, size, and morphology. This article will review the current status of angiogenesis imaging approaches, considering ultrasound, CT, MR, SPECT, PET and optical techniques with attention to their respective capabilities and limitations. As a group, these imaging methods have some potential to depict and quantify tumor microvascular features, including those considered to be functionally associated with tumor angiogenesis. Additionally, new molecule-specific imaging techniques may serve to depict those biochemical pathways and regulatory events that control blood vessel growth and proliferation. Non-invasive monitoring of anti-angiogenic therapies has great appeal and should find wide application for defining tumor microvascular and metabolic changes, because treatment-related changes in tumor morphology tend to occur rather late and are non-specific. Future developments are likely to include "fusion" or "hybrid" imaging methods. Superimposed data from MR imaging with spectroscopy, PET with CT, and PET with MR should be able to integrate advantages of different modalities yielding comprehensive information about tumor structure, function and microenvironment.
Similar articles
-
Hybrid ultrasound imaging techniques (fusion imaging).World J Gastroenterol. 2011 Jan 7;17(1):49-52. doi: 10.3748/wjg.v17.i1.49. World J Gastroenterol. 2011. PMID: 21218083 Free PMC article.
-
Non-invasive assessment of tumor neovasculature: techniques and clinical applications.Cancer Metastasis Rev. 2008 Dec;27(4):615-30. doi: 10.1007/s10555-008-9147-6. Cancer Metastasis Rev. 2008. PMID: 18506398 Review.
-
New trends in molecular imaging of tumor angiogenesis.Anticancer Agents Med Chem. 2008 Jun;8(5):497-522. doi: 10.2174/187152008784533026. Anticancer Agents Med Chem. 2008. PMID: 18537533 Review.
-
Clinical imaging of tumor angiogenesis.Future Oncol. 2012 Nov;8(11):1443-59. doi: 10.2217/fon.12.136. Future Oncol. 2012. PMID: 23148617 Review.
-
Imaging of integrin alphavbeta3 expression.Cancer Metastasis Rev. 2008 Dec;27(4):631-44. doi: 10.1007/s10555-008-9158-3. Cancer Metastasis Rev. 2008. PMID: 18523730 Review.
Cited by
-
Will magnetic resonance imaging (MRI)-based contrast agents for molecular receptor imaging make their way into the clinic?J Cell Mol Med. 2008 Jan-Feb;12(1):187-8. doi: 10.1111/j.1582-4934.2008.00248.x. Epub 2008 Jan 19. J Cell Mol Med. 2008. PMID: 18208557 Free PMC article. No abstract available.
-
Integrin imaging to evaluate treatment response.Theranostics. 2011 Feb 11;1:149-53. doi: 10.7150/thno/v01p0149. Theranostics. 2011. PMID: 21547157 Free PMC article.
-
In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications.Pharm Res. 2007 Jun;24(6):1193-201. doi: 10.1007/s11095-006-9220-1. Epub 2007 Mar 21. Pharm Res. 2007. PMID: 17373581
-
How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.Pediatr Radiol. 2022 Feb;52(2):354-366. doi: 10.1007/s00247-021-05098-5. Epub 2021 May 27. Pediatr Radiol. 2022. PMID: 34046709 Free PMC article. Review.
-
Characterization of carotid artery plaques with USPIO-enhanced MRI: assessment of inflammation and vascularity as in vivo imaging biomarkers for plaque vulnerability.Int J Cardiovasc Imaging. 2011 Jul;27(6):901-12. doi: 10.1007/s10554-010-9736-7. Epub 2010 Oct 24. Int J Cardiovasc Imaging. 2011. PMID: 20972832
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials